IRCT201103283930N5已完成2 期
Zonisamide for prevention of Atypical (Second generation) antipsychotics associated weight gain in schizophrenia : A double- blind, placebo controlled trial
Vice chancellor for research, Shiraz University of Medical Sciences0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Inclusion criteria are: age range of 16 to 65; lack of any reported neurological disease; lack of reported thyroid function problem; lack of current active substance use; lack of taking medication leading to significant weight gain or loss; no taking sulfanomides; lack of self reported kidney stone. Exclusion criteria are: lack of providing written consent; any serious medical condition such as epilepsy, thyroid function problems, diabetes; breast feeding; pregnancy; any special nutritional regime or intensive exercise program to decease weight.
排除标准
- 未提供
研究者
相似试验
尚未招募
1 期
Zonisamide a new drug drug for parkinson disease as additional drug to ongoing treatment for Parkinson: a randomized double blind placebo control studyCTRI/2019/11/022095Atul Goel
已完成
2 期
A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine HeadacheMigraine HeadacheNCT00055484Elan Pharmaceuticals204
已完成
2 期
ZEAL studyParkinson's diseaseParkinson's disease,SomnipathyD010300JPRN-jRCTs051200160Hiroshi Kataoka70
已完成
3 期
Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial SeizuresPartial SeizuresNCT00327717Eisai Inc.240
终止
3 期
A double blind, randomised, placebo-controlled, mulitcentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures.Neurological - EpilepsyepilepsyACTRN12608000096358Eisia G.C.D., Eisai Ltd.154